Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RPRXN.MX
BuyRoyalty Pharma plc · Healthcare · United States · $35.6B · Avg Vol: $48K/d
77
StockRankGet insider-trade alerts
Q
52
V
42
M
78
P/E (TTM)
33.2x
ROE
14.0%
D/E
0.9x
Dividend %
1.5%
COMPANY DESCRIPTION
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
FINANCIAL SUMMARY (MXN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.1B | 40.1B | 38.5B | 40.5B | 2.1% | 43.2B | 43.5B | 47.4B | 8.2% |
| EPS (MXN) | 1.70 | 43.25 | 32.80 | 30.48 | 161.6% | 31.58 | — | — | — |
| Shares | 443.2M | 446.7M | 446.0M | 428.7M | -3.3% | 445.3M | — | — | — |
| Debt | 121.2B | 104.5B | 129.6B | 152.4B | 7.9% | 152.6B | — | — | — |
| Equity | 95.8B | 111.1B | 118.3B | 110.3B | 4.8% | — | — | — | — |
| Op CF | 36.5B | 50.9B | 47.2B | 42.4B | 5.1% | 50.7B | — | — | — |
| Inv CF | -17.5B | -35.3B | -45.6B | -27.5B | — | — | — | — | — |
| Fin CF | -16.1B | -36.6B | 6.1B | -20.2B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+2.3%
SMA 50SMA 200
Close
$61.62
RSI (14)
68.9
52W High
$61.62
From 52W High
1.0%
SCORE BREAKDOWN
Quality
52
ROIC
9.0%70.2
ROE
14.0%80.3
GP/Assets
12.4%31.4
Op. Margin
19.7%81.3
FCF/Assets
-6.1%34.1
Piotroski
560.2
Int. Cover
4.7x52.3
D/E Ratio
0.92x16.5
Current Ratio
2.80x51.5
Value
42
P/E (TTM)
33.2x35.2
EV/EBITDA
18.0x37.5
P/FCF
—N/A
P/B
0.2x99.5
P/S
14.0x22.1
Div Yield
1.5%37.4
Momentum
78
52W High %
100%99.9
RS 6M
43%89.3
SMA 50/200
1.17x85.6
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
-44%12.1
FUNDAMENTALS
Market Cap
$35.6B
P/E (Forward)
—
Gross Margin
95.8%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RPRXN.MX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RPRXN.MX | Royalty Pharma plc(you) | $35.6B | 77 | Buy |
| CORT | Corcept Therapeutics Incorporated | $12.3B | 79 | Buy |
| REGN | Regeneron Pharmaceuticals, Inc. | $81.8B | 85 | Strong Buy |
| INCY | Incyte Corporation | $25.2B | 96 | Strong Buy |
| TECH | Bio-Techne Corporation | $11.3B | 74 | Buy |
| KRYS | Krystal Biotech, Inc. | $10.4B | 73 | Buy |
| VRTX | Vertex Pharmaceuticals Incorporated | $137.3B | 81 | Strong Buy |
| A1LN34.SA | Alnylam Pharmaceuticals, Inc. | $31.4B | 43 | Hold |
| BMRN | BioMarin Pharmaceutical Inc. | $12.5B | 60 | Hold |
| HALO | Halozyme Therapeutics, Inc. | $12.0B | 95 | Strong Buy |
Peer medians: ROE -25.0% · P/E 29.6x · Gross margin 58.8%